<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Hologic, a medical device company focused on women's health, has acquired Gynesonics, a medical device company, for USD 350 million, subject to customary closing adjustments.
      </p>
    </li>
    <li>
      <p>
        The acquisition aims to complement Hologic's offering and provide gynecologist surgeons with an expanded range of minimally invasive treatment options for women suffering from heavy periods and fibroids. 
      </p>
    </li>
    <li>
      <p>
        Gynesonics is known for developing the Sonata System, which combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation for the transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://femtechinsider.com/hologic-to-acquire-gynesonics-for-350-million-expanding-fibroid-treatment-options/">
      <b>FemTech Insider</b>
    </a>
  </p>
</div>


Next-gen Medical Devices

INCUMBENTS_PRESENT

<div>
 <p>Medical device firm Hologic, which specializes in women's health, has purchased Gynesonics, another medical device company, for $350 million. This transaction is subject to standard closing adjustments. </p>
 <p>This acquisition is intended to augment Hologic's portfolio and provide gynecologist surgeons with a more comprehensive range of minimally invasive treatment options. These are primarily for women experiencing heavy periods and fibroids. </p>
 <p>Gynesonics has been recognized for creating the Sonata System. This system merges real-time intrauterine ultrasound guidance with focused radiofrequency ablation for the transcervical treatment of certain symptomatic uterine fibroids. These fibroids include those associated with heavy menstrual bleeding. </p> 
</div>

Hologic to acquire Gynesonics for USD 350 million to expand its fibroid treatment solutions

<div>
 
 <p>CMR Surgical, a company specialising in surgical robotics, has gained FDA de novo marketing approval for its Versius surgical robotic system. This system is designed to facilitate soft tissue minimal access surgery for cholecystectomy in adults aged 22 and over.</p>
 <p>The Versius system, which earned CE mark approval in 2019, is specifically crafted for robotic minimal access surgery. It comes equipped with features such as 3D HD vision, simplified instrument control, and ergonomically designed working positions. In order to penetrate the US market, CMR Surgical is developing a strategic partnership plan with select hospitals.</p>
 
</div>

CMR Surgical receives FDA clearance for Versius surgical robot

PROMINENT_CATEGORY

<div>
 <p>Diagnostic device firm Rivanna is conducting a feasibility study for its AI-enabled Accuro XV musculoskeletal imaging system. The test will involve 200 patients to assess the safety and integration of the device into emergency department procedures. This comes after a USD 30.5 million funding from the US Biomedical Advanced Research and Development Authority in July 2023.</p>
 <p>The Accuro XV system employs ultrasound-based bone and 3D soft-tissue imaging technology, enhanced with AI software. This technology automates the detection and volumetric evaluation of skeletal fractures and soft tissue injuries. It is designed for use in emergency departments to detect soft tissue injuries in their acute phase.</p>
</div>

Rivanna begins trial for AI-enabled Accuro XV imaging system

<div>
 
 <p>TechnoPulm, a respiratory diagnostics company, has secured $2 million in seed funding from private investors and the Israel Innovation Authority. The funds will be used to ready the company's diagnostic device for market entry, initially focusing on the US.</p>
 <p>The company will invest in building its distribution and support infrastructure, including opening a subsidiary office in the United States.</p>
 <p>Based in Israel, TechnoPulm has created a handheld device capable of completing full lung function tests in just three minutes. This 400-gram portable device is meant to replace bulky, costly machines, tapping into the potential for in-office diagnostics and moving respiratory healthcare from hospitals to local community settings.</p>
 
</div>

TechnoPulm raises USD 2 million in seed funding to commercialize its handheld device

<div>
 
 <p>EchoNous, an ultrasound platform provider, is partnering with robotic technology company Mendaera to integrate their technologies.</p>
 <p>The aim of the collaboration is to enhance medical treatments by combining EchoNous' Kosmos ultrasound platform with Mendaera's handheld robotic tool. This will potentially allow healthcare providers in different specialties to carry out procedures with increased safety and precision. Post-commercialization, Mendaera will provide EchoNous Kosmos ultrasound technology as an imaging choice for its robotic clients.</p>
 
</div>

EchoNous and Mendaera partner to combine robotics and ultrasound technologies

ANALYST_QUICK_TAKE

<div>
 <p>Stryker, a leading medical technology company, has recently taken over Vertos Medical, a firm known for its speciality in interventional pain management solutions. This acquisition is particularly focused on dealing with chronic lower back pain resulting from lumbar spinal stenosis.</p>
 <p>The major aim of this strategic acquisition is to strengthen Stryker's non-surgical solutions aimed at addressing chronic lower back pain. Furthermore, it aims to expand Stryker's influence in ambulatory surgery centers. This move is expected to solidify Stryker's position in the healthcare industry.</p>
 <p>Vertos Medical has a unique portfolio, especially in the field of interventional pain management. Of notable mention is its minimally invasive mild procedure that has been helping patients suffering from chronic lower back pain regain their normal lifestyle. This specific procedure has contributed significantly to the standing of Vertos Medical and is a major factor in its acquisition by Stryker. </p>
</div> <p><b>Analyst Quicktake:<br>
 </b> Stryker continues to make M&amp;A moves across multiple applications. Other deals made during the recent months include the acquisitions of Molli Surgical ( <a href="https:<br>
//www.stryker.com/us/en/about/news/2024/stryker-completes-acquisition-of-molli-surgical.html"> July 2024 </a> ), Artelon ( <a href="https:<br>
//www.stryker.com/us/en/about/news/2024/stryker-completes-acquisition-of-artelon-inc.html"> July 2024 </a> ), and SERF SAS ( <a href="https:<br>
//www.stryker.com/us/en/about/news/2024/stryker-completes-acquisition-of-serf-sas.html"> March 2024 </a> ).</p>

Stryker acquires Vertos Medical to expand interventional pain management solutions

<div>
 
 <p>The FDA has granted premarket approval to Siemens Healthineers for PlatinumTomo, a 3D imaging technology part of their Mammomat B.brilliant mammography system. The technology is designed to reduce blur in 3D imaging, improving the accuracy of diagnosis.</p>
 <p>The Mammomat B.brilliant system utilises a 50-degree wide-angle technology. This facilitates a 50-degree image capture in under five seconds, through a quick detector and an X-ray tube with flying focal spot tech originally from CT scanners.</p>
 <p>Prior to this, the system received FDA clearance for 2D breast imaging, titanium contrast-enhanced mammography, and breast biopsy in April 2024.</p>
  
</div>

Siemens Healthineers receives FDA pre-market approval for 3D mammography technology

<div>
 
 <p>Flinn.ai, a medical device compliance software provider, received EUR 10 million (~USD 11 million) in investment from Cherry Ventures, Speedinvest, SquareOne and various business angels, including Matthias Weber and Michael Reitermann.</p>
 <p>The funds will be used to speed up market and product expansion, with a specific goal of improving its AI-driven modules for quality management and regulatory compliance.</p>
 <p>Based in Vienna, Flinn’s software platform targets mid-sized European companies, aiming to optimise regulation management. By incorporating AI technology into data processing, evaluation, and reporting, the company's SaaS solutions help manufacturers enhance the efficiency of their compliance processes.</p>
 
</div>

Flinn.ai raises EUR 10 million to expand software solution

<div>
 
 <p>Vivos Therapeutics, a company specializing in the treatment of sleep apnea, has raised a total of USD 4.3 million through a registered direct offering of common stock. Approximately 1.4 million shares are being issued at a rate of USD 3.15 per share. The exclusive placement agent for this offering is H.C. Wainwright &amp; Co.</p>
 <p>This newly acquired funding will be dedicated to fulfilling the needs of working capital and serving general corporate purposes. Given that all customary closing conditions are met, the offering is anticipated to close by or around the date of September 20, 2024.</p> 

</div>

Vivos Therapeutics raises USD 4.3 million in registered direct offering for working capital

<div>
 
 <p>Inflammatix, a company specializing in molecular diagnostics, has successfully raised USD 57 million in their Series E funding round. The round was led by Khosla Ventures and Think.Health, with contributions from D1 Capital Partners, Iberis Capital, OSF Healthcare, RAW Ventures among others.</p> 
 <p>The funds will go into facilitating regulatory filing and the early stages of the commercialization process for the company's top product, the TriVerity Acute Infection and Sepsis Test. As Inflammatix eagerly awaits FDA clearance, anticipated to be granted later this year, this test is instrumental in measuring gene expression levels in blood associated with immune reactions. The results of the test are typically delivered in around 30 minutes.</p>
  
</div>

All Updates

Hologic to acquire Gynesonics for USD 350 million to expand its fibroid treatment solutions

CMR Surgical receives FDA clearance for Versius surgical robot

Rivanna begins trial for AI-enabled Accuro XV imaging system

TechnoPulm raises USD 2 million in seed funding to commercialize its handheld device

EchoNous and Mendaera partner to combine robotics and ultrasound technologies

Stryker acquires Vertos Medical to expand interventional pain management solutions

Siemens Healthineers receives FDA pre-market approval for 3D mammography technology

Flinn.ai raises EUR 10 million to expand software solution

Vivos Therapeutics raises USD 4.3 million in registered direct offering for working capital

Inflammatix raises USD 57 million in Series E funding for commercialization

Next-gen Medical Devices

Hologic to acquire Gynesonics for USD 350 million to expand its fibroid treatment solutions

Contact us